0000899243-22-001525.txt : 20220110 0000899243-22-001525.hdr.sgml : 20220110 20220110203556 ACCESSION NUMBER: 0000899243-22-001525 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220106 FILED AS OF DATE: 20220110 DATE AS OF CHANGE: 20220110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cheng Isaac CENTRAL INDEX KEY: 0001829696 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41199 FILM NUMBER: 22522542 MAIL ADDRESS: STREET 1: C/O ATEA PHARMACEUTICALS, INC. STREET 2: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464600503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-683-0917 MAIL ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-01-06 0 0001658551 Amylyx Pharmaceuticals, Inc. AMLX 0001829696 Cheng Isaac C/O AMYLYX PHARMACEUTICALS, INC. 43 THORNDIKE STREET CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2022-01-06 4 C 0 1409035 A 1409035 I See Footnote Common Stock 2022-01-06 4 C 0 6410964 A 7819999 I See Footnote Common Stock 2022-01-06 4 C 0 974107 A 8794106 I See Footnote Common Stock 2022-01-06 4 C 0 1621544 A 10415650 I See Footnote Common Stock 2022-01-06 4 P 0 6578 19.00 A 6578 D Series A Preferred Stock 2022-01-06 4 C 0 1409035 0.00 D Common Stock 1409035 0 I See Footnote Series B Preferred Stock 2022-01-06 4 C 0 6410964 0.00 D Common Stock 6410964 0 I See Footnote Series C-1 Preferred Stock 2022-01-06 4 C 0 974107 0.00 D Common Stock 974107 0 I See Footnote Series C-2 Preferred Stock 2022-01-06 4 C 0 1621544 0.00 D Common Stock 1621544 0 I See Footnote Stock Option (Right to Buy) 19.00 2022-01-06 4 A 0 8400 0.00 A 2032-01-06 Common Stock 8400 8400 D Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares. This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. /s/ Joshua B. Cohen, as Attorney-in-Fact 2022-01-10